Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021

IMPORTANCE: Targeted therapies for EGFR (OMIM 131550)– and ALK (OMIM 105590)–altered metastatic non–small cell lung cancer (NSCLC) substantially improve outcomes for some patients. However, use of these therapies is lower among Medicaid patients, and access to oncology care varies across state Medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Thomas J., Kesselheim, Aaron S., Avorn, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187487/
https://www.ncbi.nlm.nih.gov/pubmed/36696113
http://dx.doi.org/10.1001/jamanetworkopen.2022.52562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187487/
https://www.ncbi.nlm.nih.gov/pubmed/36696113
http://dx.doi.org/10.1001/jamanetworkopen.2022.52562

Ejemplares similares